CD8A and neoplasm: The hydrogel enables sustained local release of therapeutic agents to eradicate residual tumor cells via DOX CMT and PD-L1 blockade-enhanced CD8+ T cell immunity, while simultaneously promoting bone regeneration through scaffold-functionalized osteogenesis in critical-sized defects.